Civil society groups are again calling for the Chilean government to issue compulsory licenses for Astellas Pharma Inc.’s prostate cancer drug Xtandi (enzalutamide) and hepatitis C treatments containing Gilead Sciences Inc.’s sofosbuvir. The move comes after lawmakers passed a resolution calling for the government to introduce measures to facilitate compulsory licensing.
Some 29 patient groups and NGOs from around the world – including Oxfam, Health Action International, Knowledge Ecology International, Colombia’s...







